Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,201–2,300 of 4,628
Fu, C., Chen, L., Cheng, Y., Yang, W., Zhu, H., Wu, X., & Cai, B. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1114601 · Cited by 15
“Anti-fibrotic drugs (Pirfenidone and Nintedanib) have been approved to treat IPF, but they only slow the decline in lung function in IPF patients and do not improve survival (King et al., 2014; Richeldi et al., 2014).”
BackgroundSelf-management interventions for people with pulmonary fibrosis: a scoping review
Lee, J. Y. T., Tikellis, G., Dowman, L., Jones, A. W., Hoffman, M., Mellerick, C., Malaguti, C., Khor, Y. H., & Holland, A. E. (2023) · European Respiratory Review · doi:10.1183/16000617.0092-2023 · Cited by 13
Kürner, T. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.09.001 · Cited by 12
“BI has recently completed two large global clinical trials of nintedanib (INPULSISTM) for the treatment of IPF [10].”
BackgroundMethodOkuda, R., Matsushima, H., Oba, T., Kawabe, R., Matsubayashi, M., Amano, M., Nishizawa, T., & Honda, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.10.001 · Cited by 15
“Some clinical trials have reported that FVC decreased by approximately 150–240 mL over a 12-month period in patients with mild to moderate IPF who were administered placebo [8,22]; on the other hand, in the present study, FVC decreased by as much as 170 mL over a 26-week period prior to N-acetylcysteine therapy.”
BackgroundBennett, D., Fossi, A., Refini, R. M., Gentili, F., Luzzi, L., Voltolini, L., Paladini, P., Mazzei, M. A., & Rottoli, P. (2016) · Tumori Journal · doi:10.5301/tj.5000557 · Cited by 12
Vartiainen, V. A., Raula, J., Bimbo, L. M., Viinamäki, J., Backman, J. T., Ugur, N., Kauppinen, E. I., Sutinen, E., Joensuu, E. I., Koli, K. M., et al. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.04.019 · Cited by 15
“In phase 3 clinical trials, over 90% of the patients reported at least one adverse effect (18, 37).”
BackgroundNew treatment paradigms for connective tissue disease-associated interstitial lung disease
Kouranos, V., Miranda, G., Corte, T. J., & Renzoni, E. A. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000508 · Cited by 12
Scleroderma-related interstitial lung disease: principles of management
Das, A., Kumar, A., Arrossi, A. V., Ghosh, S., & Highland, K. B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1575732 · Cited by 12
“Nintedanib is a tyrosine kinase inhibitor that targets several pathways including vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor [66].”
BackgroundInfluentialDesign of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies
Kaner, R. J., Bajwa, E. K., El-Amine, M., Gorina, E., Gupta, R., Lazarus, H. M., Luckhardt, T., Mouded, M., Posada, K., Richeldi, L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0592pp · Cited by 14
Self-citationIdiopathic Pulmonary Fibrosis and Lung Cancer: Finding Similarities within Differences
Reyfman, P. A., & Gottardi, C. J. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0172ed · Cited by 12
Nintedanib-induced glomerular microangiopathy: a case report
Hasegawa, M., Uehara, A., Suzuki, T., Sekine, R., Yazawa, M., Ichikawa, D., Koike, J., & Shibagaki, Y. (2020) · CEN Case Reports · doi:10.1007/s13730-020-00474-w · Cited by 15
the FIBRONET study group, Poletti, V. E., Vancheri, C., Albera, C., Harari, S. A., Pesci, A., Metella, R. R., Campolo, B., Crespi, G., & Rizzoli, S. (2021) · Respiratory Research · doi:10.1186/s12931-021-01643-w · Cited by 13
Pterostilbene alleviates pulmonary fibrosis by regulating ASIC2
Peng, Y., Zhang, Y., Zhang, Y., Wang, X., Xia, Y., Ye, T., Wu, Z., & Ke, H. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00474-7 · Cited by 13
Iwanami, Y., Ebihara, K., Nakao, K., Sato, N., Miyagi, M., Nakamura, Y., Sakamoto, S., Kishi, K., Homma, S. A., & Ebihara, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185336 · Cited by 15
Pulmonary Abscess as a Complication of Transbronchial Lung Cryobiopsy
Skalski, J. H., Kern, R. M., Midthun, D. E., et al. (2015) · Journal of Bronchology & Interventional Pulmonology · doi:10.1097/lbr.0000000000000182 · Cited by 12
Ikeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., et al. (2022) · Medicine · doi:10.1097/md.0000000000029232 · Cited by 11
From Epithelium to Therapy: Transitional Cells in Lung Fibrosis
Shin, S. Y., Chen, J., Krentsis, I. M., Reisner, Y., Abrencillo, R., Hussain, R., Wu, D., & Karmouty‐Quintana, H. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0372tr · Cited by 20
Lee, J. H., Jang, J. H., Lee, S., & Her, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412126 · Cited by 17
“The clinical efficacy of nintedanib, a tyrosine kinase inhibitor targeting PDGFR, FGFR, and VEGRF [190], across IPF [191], systemic sclerosis-ILD [192], and progressive fibrosing CTD-ILD [193] underscores the centrality of these interconnected growth-factor pathways in autoimmune-driven lung…”
Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis
Porse, S., Hoyer, N., & Shaker, S. B. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.107015 · Cited by 12
Chubachi, S., Okamori, S., Yamada, Y., Yamada, M., Yokoyama, Y., Niijima, Y., Kamata, H., Ishii, M., Fukunaga, K., & Jinzaki, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-24157-x · Cited by 11
Hashemian, S. M. R., Farhadi, T., Varahram, M., & Velayati, A. A. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2153116 · Cited by 11
Yüksel, R., Yüksel, N., Yazır, Y., Öztürk, A., Rençber, S. F., & KÜÇÜK, K. D. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109431 · Cited by 12
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
Pugashetti, J. V., Khanna, D., Kazerooni, E. A., & Oldham, J. M. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.012 · Cited by 14
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00730-y · Cited by 12
Recent Advances (2015–2020) in Drug Discovery for Attenuation of Pulmonary Fibrosis and COPD
Dorababu, A., & Maraswami, M. (2023) · Molecules · doi:10.3390/molecules28093674 · Cited by 15
“A clinical trial report revealed that nintedanib reduced lung-function decline and acute exacerbations [6].”
BackgroundRautajoki, T., Lehto, J. T., Sutinen, E., Bergman, P., Sintonen, H., Rajala, K., Mäkelä, K., Hollmén, M., Saarto, T. H., & Myllärniemi, M. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0548 · Cited by 13
Sevilla, J. P. H., Memon, A., & Hinchcliff, M. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03090-y · Cited by 13
Shuvaev, S., Knipe, R. S., Drummond, M., Rotile, N. J., Ay, İ., Weigand‐Whittier, J., Ma, H., Zhou, I. Y., Roberts, J. D., Black, K., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01845-2 · Cited by 11
No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
Hoffman, T. W., van Moorsel, C. H. M., van der Vis, J. J., Biesma, D. H., & Grutters, J. C. (2023) · ERJ Open Research · doi:10.1183/23120541.00131-2023 · Cited by 14
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2281416 · Cited by 11
Self-citationOkamoto, M., Fujimoto, K., Johkoh, T., Kawaguchi, A., Mukae, H., Sakamoto, N., Ogura, T., Ikeda, S., Kondoh, Y., Yamano, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49180-4 · Cited by 16
Self-citationBufotalin attenuates pulmonary fibrosis via inhibiting Akt/GSK-3β/β-catenin signaling pathway
Yin, J.-Z., Li, Z.-Q., Zhang, X., Wan, Z.-J., Qin, H.-R., Yao, L.-H., Li, B.-L., 高福, & Yang, Y.-Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176293 · Cited by 11
Advances in lung transplantation: 60 years on
Paraskeva, M. A., & Snell, G. I. (2024) · Respirology · doi:10.1111/resp.14721 · Cited by 18
“118,119 Given their impact on fibroblast proliferation there is growing interest in whether these drugs could impact the development of OB associated with BOS and the parenchymal and interstitial fibrosis associated with RAS.”
BackgroundGhanem, M., Archer, G., Crestani, B., & Mailleux, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108669 · Cited by 14
Wang, T., Xu, L., Li, P., Zhang, C.-H., Zhang, C.-H., Wang, X., Xiang, L., Xu, Z.-P., & Shen, T. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155797 · Cited by 13
Fujiwara, Y., Shimomura, K., Yamaguchi, T., Shimizu, J., Watanabe, N., Matsuzawa, R., Murotani, K., & Horio, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1419256 · Cited by 12
Patient-centered care in pulmonary fibrosis: access, anticipate, and act
Hofman, D. E., Magrì, T., Moor, C. C., Richeldi, L., Wijsenbeek, M. S., & Waseda, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02997-7 · Cited by 15
Self-citationDynapenia and Sarcopenia as Risk Factors for Mortality in Interstitial Lung Disease
Ibarra‐Fernández, A. A., Robles-Hernández, R. E., Orea‐Tejeda, A., González‐Islas, D., Jiménez‐Valentín, A., Sánchez‐Santillán, R., Arcos‐Pacheco, L. P., Gutiérrez‐Luna, E., Zurita‐Sandoval, A., Espinosa, T. P., et al. (2025) · Respirology · doi:10.1111/resp.14892 · Cited by 13
Mısırcı, S., Ekin, A., Yağız, B., Coşkun, B. N., Başıbüyük, F., Birlik, A. M., Sarı, İ., Karaca, A. D., Koca, S. S., Çetin, G. Y., et al. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07323-0 · Cited by 20
“In phase III clinical trials with NTD for the treatment of idiopathic pulmonary fibrosis (INPULSIS-1 and INPUL-SIS-2), NTD was shown to reduce the decline in percentage predicted forced vital capacity (%pFVC) and has become a new treatment option [11].”
Fibrotic Pulmonary Sarcoidosis—From Pathogenesis to Management
Łyżwa, E., Wakuliński, J., Szturmowicz, M., Tomkowski, W. Z., & Sobiecka, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072381 · Cited by 14
“Recent studies have shown beneficial antifibrotic effects of the two drugs nintedanib and pirfenidone in the treatment of patients with IPF, and nintedanib in the treatment of patients with interstitial lung disease with progressive fibrosis [92,154–156].”
Zheng, S., Zhou, Z., Ji, J., Liu, Y., Jiao, X., Li, X., Shen, Y., Hong, H., & Han, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113862 · Cited by 17
Kondoh, Y., Fujii, T., Inoue, Y., & Atsumi, T. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103900 · Cited by 14
Self-citationNintedanib for the treatment of patients with advanced non-small-cell lung cancer
Reck, M., Heigener, D. F., & Reinmuth, N. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.945430 · Cited by 11
Novel approaches to pulmonary fibrosis
Jenkins, G. R., & Goodwin, A. T. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s45 · Cited by 11
Chérrez-Ojeda, I., Cottin, V., Calderón, J. C., Delgado, C., Calero, E., Simancas‐Racines, D., Quadrelli, S., & Chérrez, A. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0569-1 · Cited by 11
Self-citationBrooks, D. L. P., Zimmer, A. S., Wakefield, L. M., Lyle, L. T., Difilippantonio, S., Tucci, F. C., Illiano, S., Annunziata, C. M., & Steeg, P. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25231 · Cited by 14
Medical Treatments of Peyronie's Disease: Past, Present, and Future
Mohede, D. C. J., de Jong, I. J., & van Driel, M. F. (2019) · Urology · doi:10.1016/j.urology.2019.01.001 · Cited by 14
Assessment and Management of Occupational Hypersensitivity Pneumonitis
Ojanguren, Í., Ferraro, V., Morisset, J., Muñoz, X., Fink, J. N., & Cruz, M. J. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.09.002 · Cited by 12
Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis
LANCASTER, L. H., Fieuw, A. M., Meulemans, J., Ford, P., & Nathan, S. D. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106227 · Cited by 11
Xiaohong, X., Liqiang, W., Na, L., Xinqing, L., Yin-yin, Q., Ming, L., Ming, O., Qian, H., Qun, L., Li, S., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.660800 · Cited by 10
Kelly, B. T., Thao, V., Dempsey, T. M., Sangaralingham, L. R., Payne, S. R., Teague, T., Moua, T., Shah, N. D., & LIMPER, A. H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01607-2 · Cited by 12
Defining and predicting progression in non-IPF interstitial lung disease
Goos, T., Sadeleer, L. D., Yserbyt, J., Langhe, E. D., Dubbeldam, A., Verbeken, E. K., Verleden, G. M., Vermant, M., Verschakelen, J., Vos, R., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106626 · Cited by 14
Bernardinello, N., Grisostomi, G., Cocconcelli, E., Castelli, G., Petrarulo, S., Biondini, D., Saetta, M. P., Spagnolo, P., & Balestro, E. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106686 · Cited by 16
Kreuter, M., Maher, T. M., Corte, T. J., Molina‐Molina, M., Axmann, J., Gilberg, F., Kirchgaessler, K.-U., & Cottin, V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02009-w · Cited by 11
Self-citationPleiotropic Long-Term Effects of Atorvastatin on Posttraumatic Joint Contracture in a Rat Model
Wegner, E., Slotina, E., Mickan, T., Truffel, S., Arand, C., Wagner, D., Ritz, U., Rommens, P. M., Gercek, E., Drees, P., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030523 · Cited by 13
Lee, J.-U., Choi, J. S., Kim, M. K., Min, S. A., Park, J., & Park, C. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.442 · Cited by 11
The Efficacy of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis
Choi, H. E., Kim, T. H., Jang, J. H., Jang, H. J., Yi, J., Jung, S. Y., Kim, D.-W., & Lee, J. H. (2023) · Life · doi:10.3390/life13020403 · Cited by 12
“Although IPF is chronically progressive, antifibrotic therapy halves the decline in lung function and is effective in preventing acute exacerbation [4,5].”
BackgroundSelf-citationDecoding the role of fatty acids and their metabolites in lung fibrosis
Wygrecka, M., Hadžić, S., Potaczek, D. P., Alexopoulos, I., Agha, E. E., & Schaefer, L. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16520 · Cited by 14
Imaging Features of Idiopathic Interstitial Lung Diseases
Batra, K., & Adams, T. N. (2023) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000728 · Cited by 11
Ye, Y., Sing, C., Hubbard, R., Lam, D. C. L., Li, H., Li, G. H., Ho, S., & Cheung, C. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100871 · Cited by 24
Lee, J. H., & Song, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-946 · Cited by 15
Therapeutic advances in idiopathic pulmonary fibrosis
George, G., Vaid, U., & Summer, R. S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.283 · Cited by 11
Advances in the treatment of idiopathic pulmonary fibrosis
Sergew, A., & Brown, K. M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1102886 · Cited by 12
Self-citationMultidisciplinary discussion for diagnosis of interstitial lung disease in real life
Guler, S. A., Berezowska, S., Christe, A., et al. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14318 · Cited by 11
Brown, K. K. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.036 · Cited by 11
Self-citationInterstitial lung abnormalities: risk and opportunity
Ash, S. Y., & Washko, G. R. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30006-1 · Cited by 11
Sex steroid receptor expression in idiopathic pulmonary fibrosis
Mehrad, M., Bittar, H. E. T., & Yousem, S. A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.02.012 · Cited by 12
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton, C., & Chaudhuri, N. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0488-0 · Cited by 15
Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?
Duarte, A. C., Santos, M. J., & Cordeiro, A. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3867-3 · Cited by 11
Siroux, V., & Crestani, B. (2018) · European Respiratory Journal · doi:10.1183/13993003.02663-2017 · Cited by 11
Oldham, J. M., Witt, L. J., Adegunsoye, A., Chung, J. H., Lee, C. T., Hsu, S., Chen, L. W., Husain, A. N., Montner, S. M., Vij, R., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0599-3 · Cited by 11
Economic consequences of idiopathic pulmonary fibrosis in Denmark
Hilberg, O., Bendstrup, E. M., Ibsen, R., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00045-2017 · Cited by 11
Song, Z., Huang, S., He, Y., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.046 · Cited by 11
McLellan, T., George, P. M., Ford, P., Backer, J. D., Holsbeke, C. S. V., Mignot, B., Screaton, N. J., Ruggiero, A., & Thillai, M. (2020) · ERJ Open Research · doi:10.1183/23120541.00290-2019 · Cited by 11
Diridollou, T., Sohier, L., Rousseau, C., Angibaud, A., Chauvin, P., Gaignon, T., Tas, M., Lemerre, J., Kerjouan, M., Salé, A., et al. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.02.004 · Cited by 14
“Chest CT-scan is now prominent in the management of those patients, in order to obtain an accurate, early diagnosis needed for treatment with the anti-fibrotic drug that have recently become available (3,4).”
BackgroundArshad, M. N., Ahmed, K., Iqbal, Z. M., et al. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.128880 · Cited by 11
Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians
Houron, C., Danielou, M., Mir, O., Fromenty, B., Perlemuter, G., & Voican, C. S. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103127 · Cited by 14
Antoniou, K. M., Tsitoura, E., Vasarmidi, E., Symvoulakis, E. K., Aidinis, V., Tzilas, V., Τzouvelekis, Α., & Bouros, D. E. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.12.007 · Cited by 12
Lye, T. H., Roshankhah, R., Karbalaeisadegh, Y., Montgomery, S. A., Egan, T. M., Muller, M. M., & Mamou, J. (2021) · The Journal of the Acoustical Society of America · doi:10.1121/10.0005481 · Cited by 13
PROMising developments in IPF patient-reported outcome measures
Nolan, C. M., & Birring, S. S. (2022) · European Respiratory Journal · doi:10.1183/13993003.02312-2021 · Cited by 12
Wilson, A. C., Chiles, J. W., Ashish, S. Y., Chanda, D., Kumar, P. L., Mobley, J. A., Neptune, E., Thannickal, V. J., & McDonald, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-07151-1 · Cited by 14
Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Amubieya, O., Ramsey, A. L., Derhovanessian, A., Fishbein, G. A., Lynch, J. P., Belperio, J. A., & Weigt, S. S. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1729175 · Cited by 11
Preferential PDE4B Inhibition — A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis
Chambers, R. C. (2022) · New England Journal of Medicine · doi:10.1056/nejme2205411 · Cited by 13
Li, K., Liu, P., Zhang, W., Liu, X., Tanino, Y., Koga, Y., & Yan, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3700 · Cited by 12
When and how important is anti-fibrotic therapy in the post-COVID-19 period?
Kerget, B., Çil, G., Araz, Ö., Alper, F., & Akgün, M. (2022) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2022_105 · Cited by 14
Bruni, C., Campochiaro, C., & Vries-Bouwstra, J. K. D. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.01.005 · Cited by 13
Thabut, G., Crestani, B., Porcher, R., & Richeldi, L. (2015) · European Respiratory Journal · doi:10.1183/13993003.02204-2014 · Cited by 10
Self-citationTroy, L. K., Chapman, S. A., Lake, F., WILSHER, M. L., Honeysett, L., Macansh, S., & Corte, T. J. (2015) · Respirology · doi:10.1111/resp.12512 · Cited by 11
Update in Interstitial Lung Disease 2014
Belloli, E. A., Martínez, F. J., & Flaherty, K. R. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0768up · Cited by 10
Self-citationBioluminescent kinase strips: A novel approach to targeted and flexible kinase inhibitor profiling
Hennek, J., Alves, J., Yao, E., Goueli, S. A., & Zegzouti, H. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.11.007 · Cited by 15
Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
Oda, K., Matsunaga, T., Sennari, K., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.8065 · Cited by 11
The Role of Immunity and Inflammation in IPF Pathogenesis
Butler, M. W., & Keane, M. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_6 · Cited by 14
Panchabhai, T. S., Arrossi, A. V., Highland, K. B., Bandyopadhyay, D., Culver, D. A., Budev, M. M., & Farver, C. F. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0778-x · Cited by 12
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10
“George’s Respiratory Questionnaire (SGRQ) and UCSD-SOBQ were used to assess response to anti-fibrotic therapy in terms of dyspnea and health-related quality of life, noting little measurable improvement from placebo in the treatment arms [25,26].”
MethodCombined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice
Bai, L., Wang, J., Wang, X., Wang, J., Zeng, W., Pang, J., Zhang, T., Li, S., Song, M., Shi, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17390 · Cited by 15
Kreuter, M., Maher, T. M., Wuyts, W. A., Valenzuela, C., Hamblin, M., Kim, S., Patel, A., Elpers, B., & Richeldi, L. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.04.003 · Cited by 15
Self-citationLiu, S., Wang, Q., Min, J., Zhang, Y., Zhang, Y., Yang, J., Tan, Y., Tan, L., Yin, M., Zhang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64211-6 · Cited by 20
Senhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 15
Hot off the breath: a big step forward for idiopathic pulmonary fibrosis
Ryerson, C. J., & Collard, H. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205892 · Cited by 10
Self-citationCarr, Z. J., Yan, L., Chavez-Duarte, J., Zafar, J., & Oprea, A. D. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s266217 · Cited by 17
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.